Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 15 - Drugs for genital or sexual disorders; Contraceptives
Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635)
08/2003
08/21/2003WO2003068169A2 Stabilized synthetic immunogen delivery system
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003044056A3 Chemically-modified human growth hormone conjugates
08/21/2003WO2003027075A3 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
08/21/2003WO2002088664A3 Control of compactability through crystallization
08/21/2003WO2002085384A3 Lubricious coatings for substrates
08/21/2003WO2002064748A3 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/21/2003WO2001092581A3 Compositions and methods for the therapy and diagnosis of ovarian cancer
08/21/2003WO2001060162A9 Cationic, amphipathic beta-sheet peptides and uses thereof
08/21/2003US20030158469 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
08/21/2003US20030158413 A thiochromane-7-carboxamide derivatives as Rho kinase enzyme inhibitor; nontoxic, anticancer agents
08/21/2003US20030158409 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158219 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
08/21/2003US20030158217 Succinate and malonate complexes treatment of abnormal cell growth, such as cancer, and overexpression of erbB2, and inducing cell death
08/21/2003US20030158209 Amidomethylcarbonyl-substituted piperazine derivatives containing additional amine groups, useful in treating eating, sexual and skin disorders
08/21/2003US20030158206 Sildenafil mesylate for the treatment of male erectile dysfunction or female sexual disorders.
08/21/2003US20030158197 Certain alkylene diamine-substituted heterocycles
08/21/2003US20030158192 Activating cytokine biosynthesis, viricides treating a viral disease, antitumor agents, immunomodulators
08/21/2003US20030158182 Cyanopyrroles
08/21/2003US20030158173 NK 1 antagonists
08/21/2003US20030158168 Composition for combined use of aromatase inhibitors
08/21/2003US20030158164 Novel antiandrogenic agent
08/21/2003US20030158160 Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
08/21/2003US20030158106 Use of fsh for treating infertility
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030158096 Novel molecule
08/21/2003US20030157707 Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro
08/21/2003US20030157482 Binding labeled antibody to protein; measurement; calibration
08/21/2003US20030157208 Plant extracts obtained from solvent extraction, for treating sexual disorders
08/21/2003US20030157099 Human trk receptors and neurotrophic factor inhibitors
08/21/2003US20030157086 Administering antagonist to sphingomyelinase gene product;side effect reduction of cancer therapy
08/21/2003DE19937304C2 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen Use of CGRP antagonists for the control of menopausal hot flushes
08/21/2003CA2475838A1 Cytotoxic t-cell epitopes from chlamydia
08/21/2003CA2475783A1 Benzenesulfonamide derivatives as antipsychotic agents
08/21/2003CA2475102A1 Stabilized synthetic immunogen delivery systems
08/21/2003CA2474171A1 Biphenil derivatives and their use as antiandrogenic agents
08/21/2003CA2472822A1 Chemical compounds
08/21/2003CA2472762A1 2-oxazolamines and their use as 5-ht2b receptor antagonists
08/20/2003EP1335923A2 Condensed pyridoindole derivatives
08/20/2003EP1335917A2 Condensed pyridoindole derivatives
08/20/2003EP1335907A1 Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
08/20/2003EP1335901A1 Pharmaceutically active sulfanilide derivatives
08/20/2003EP1335730A1 Treatment of premature ejaculation
08/20/2003EP1212327B1 Pyrazolopyrimidines as therapeutic agents
08/20/2003EP1053233B1 Hydroxamic and carboxylic acid derivatives
08/20/2003EP0831829B1 Heterocyclic ring-fused pyrimidine derivatives
08/20/2003EP0813417B1 Use of hyaluronic acid for the treatment of interstitial cystitis
08/20/2003CN1437599A Tryasolyl tropane derivatives for therapy
08/20/2003CN1437595A Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals
08/20/2003CN1437591A Compounds and methods for modulation of estrogen receptors
08/20/2003CN1437589A Process for the preparation of pyrazolopyrimidin ones
08/20/2003CN1437463A System and method for treating a mucosal surface
08/20/2003CN1436790A Fowl castration vaccine gene and recombinant gene vector
08/20/2003CN1436568A Prepn of medicine for treating male's sterility
08/20/2003CN1436565A Externally applied medicine for treating uterine erosion and its preparing method
08/20/2003CN1436546A Prepn of women's inflammation diminishing film prepn
08/20/2003CN1436543A Chinese medicine for treating sterility and its prepn process
08/20/2003CN1436525A Fimbriate orostachys herb suppository and its prepn process
08/20/2003CN1118459C Pyrimidinedione, pyrimidi netrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-adrenergic receptor antagonists
08/20/2003CN1118451C Acylated derivatives of melatonin and its analogues as medicine
08/19/2003US6608203 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
08/19/2003US6608197 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
08/19/2003US6608089 Derivatives of flavones, xanthones and coumarins
08/19/2003US6608074 Administering during follicular phase of female menstrual cycle and in luteal phase, a competitive progesterone antagonist, which is less than an ovulation-inhibiting dose and less than an abortion-inductive dose
08/19/2003US6608068 Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents
08/19/2003US6608065 Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction
08/19/2003US6608063 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
08/19/2003US6607757 At least 13% glucoside isoflavones and 0.6-1.5 parts 3 soya saponins per 1 part by weight of glucoside isoflavones; treating pre or post menopausal symptoms, breast and prostate cancer, and alcoholism
08/19/2003US6607753 Converting extract of Tribulus furostanol saponin compounds to spirostanol compounds; hydrolysis, separation; topical application
08/19/2003CA2099061C Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
08/19/2003CA2079376C (bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
08/14/2003WO2003066860A1 Angiogenesis inhibitors
08/14/2003WO2003066859A2 Amino acid sequences capable of facilitating penetration across a biological barrier
08/14/2003WO2003066621A1 Piperidine derivatives and their use as antagonists of tachykinins
08/14/2003WO2003066620A1 Dihydro-thia-phenanthrene-carbonyl-guanidines, method for the production thereof, use thereof as a medicament or diagnostic reagent
08/14/2003WO2003066594A2 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
08/14/2003WO2003066585A2 Polymer-based compositions for sustained release
08/14/2003WO2003066077A2 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
08/14/2003WO2003066061A1 Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
08/14/2003WO2003066050A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
08/14/2003WO2003066030A2 Pharmaceutical tablet
08/14/2003WO2003066029A2 Pharmaceutical dosage form for mucosal delivery
08/14/2003WO2003066001A2 Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
08/14/2003WO2003065924A1 Control of a biological function
08/14/2003WO2003048183A3 Method for obtaining oestrogen from mare urine
08/14/2003WO2003037335A8 5-heteroatom-substituted pyrazoles
08/14/2003WO2003031568A8 Intracellular signaling molecules
08/14/2003WO2002081430A3 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
08/14/2003WO2002064083A3 Synthesis of 3-amino-thalidomide and its enantiomers
08/14/2003WO2002058703A3 The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers
08/14/2003WO2002057453A3 Polypetides and nucleic acids encoding same
08/14/2003WO2002043807A3 Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
08/14/2003WO2002029055A3 Carbohydrate-associated proteins
08/14/2003WO2002015933A3 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
08/14/2003WO2002011714A3 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
08/14/2003WO2001092527A3 Regulators of apoptosis
08/14/2003US20030153808 Implantation rate using ff-mas
08/14/2003US20030153625 Suppressing bone disordes such as decalcification or fractures in humans having prostate gland cancers by administering antiestrogen selected from triphenylethylene or toremifene; hormone inhibitors
08/14/2003US20030153621 Administering mixtures of 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE) and carriers comprising glycerides or fatty esters as controllers of endothelial growth factors
1 ... 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 ... 557